Triple

T22041580
Position Surface form Disambiguated ID Type / Status
Subject Extra Help program E544647 entity
Predicate legalBasis P125 FINISHED
Object Medicare Prescription Drug, Improvement, and Modernization Act of 2003 NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Medicare Prescription Drug, Improvement, and Modernization Act of 2003 | Statement: [Extra Help program, legalBasis, Medicare Prescription Drug, Improvement, and Modernization Act of 2003]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Medicare Prescription Drug, Improvement, and Modernization Act of 2003
Context triple: [Extra Help program, legalBasis, Medicare Prescription Drug, Improvement, and Modernization Act of 2003]
  • A. Medicare Prescription Drug, Improvement, and Modernization Act of 2003 chosen
    The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
  • B. Food and Drug Administration Amendments Act of 2007
    The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
  • C. Prescription Drug User Fee Act of 1992
    The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
  • D. Medicaid Drug Rebate Program
    The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
  • E. Drug Price Competition and Patent Term Restoration Act of 1984
    The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e11e32445c8190ab97089b48a130bb completed April 16, 2026, 5:36 p.m.
NER Named-entity recognition batch_69f12829c1c081909edc7544242c9c7a completed April 28, 2026, 9:35 p.m.
Created at: April 16, 2026, 8:25 p.m.